Login to Your Account

Aerie gets present from the FDA in Rhopressa early nod

By Brian Orelli
Staff Writer

Tuesday, December 19, 2017

Christmas came early for Aerie Pharmaceuticals Inc. with an FDA approval of Rhopressa (netarsudil) for open-angle glaucoma or ocular hypertension on Monday – or maybe call it an early Valentine's Day gift considering the PDUFA goal date wasn't until Feb. 28, 2018.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription